A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers.

MiMedx Group, Inc.5 sites in 1 country98 target enrollmentMarch 2012

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Venous Leg Ulcer
Sponsor: MiMedx Group, Inc.
Enrollment: 98
Locations: 5
Primary Endpoint: The proportion of wounds achieving 40% closure in patients treated with amniotic membrane vs. standard of care
Status: Completed
Last Updated: 10 years ago

The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

Registry

clinicaltrials.gov

Start Date

March 2012

End Date

May 2014

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Responsible Party

Sponsor

•At least 18 years old
•Ankle Brachial Pressure Index (ABI) \> 0.75
•Presence of a venous leg ulcer extending through the full thickness of the skin but not down to muscle, tendon or bone
•Study ulcer has been present for at least one month prior to the initial screening visit, and is excluded if it has undergone 12 months of continuous high strength compression therapy over its duration
•Study ulcer is a minimum of 2 cm2 and a maximum of 20 cm2 at the Randomization visit
•The target ulcer has been treated with compression therapy for at least 14 days prior to randomization
•Ulcer has a clean, granulating base with minimal adherent slough at the Randomization visit
•Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
•Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen
•Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken

•Study ulcer(s) deemed by the investigator to be caused by a medical condition other than venous insufficiency
•Study ulcer exhibits clinical signs and symptoms of infection.
•Non-mobile i.e. not ambulatory, or bed ridden
•Study ulcer, in the opinion of the investigator, is suspicious for cancer should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
•Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
•Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding Screening
•History of radiation at the ulcer site
•Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
•Study ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days
•Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the course of the trial.

The proportion of wounds achieving 40% closure in patients treated with amniotic membrane vs. standard of care

Time Frame: 4 week

The proportion of wounds achieving 40% closure in patients treated with one application of amniotic membrane vs. standard of care(4 week)
The proportion of wounds achieving 40% closure in patients treated with two applications of amniotic membrane vs. standard of care(4 week)
The proportion of wounds achieving 40% closure in patients treated with one application of amniotic membrane vs. 2 applications of amniotic membrane(4 week)